

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

ATR Antibody

RRID:AB_2227860

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2790, RRID:AB_2227860

Antibody Information

URL: http://antibodyregistry.org/AB_2227860

Proper Citation: Cell Signaling Technology Cat# 2790, RRID:AB_2227860

Target Antigen: ATR

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: ATR Antibody

Description: This polyclonal targets ATR

Target Organism: b, dg, rat, hm, hamster, h, canine, m, mouse, r, bovine, human, mk

Antibody ID: AB_2227860

Vendor: Cell Signaling Technology

Catalog Number: 2790

Record Creation Time: 20250819T205325+0000

Record Last Update: 20250819T210914+0000

Ratings and Alerts

No rating or validation information has been found for ATR Antibody.

No alerts have been found for ATR Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Planas-Paz L, et al. (2026) Targeting ATR signaling in sarcoma with homologous recombination deficiency. Cancer letters, 642, 218300.

Haas A, et al. (2025) Wnt10b signaling regulates replication stress-induced chromosomal instability in human cancer. Life science alliance, 8(11).

Wang Q, et al. (2025) Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss. Cancer research communications, 5(6), 994.

Herv?? S, et al. (2025) Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint. Nature cell biology, 27(1), 73.

Cheng J, et al. (2024) Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling. Cell reports. Medicine, 5(8), 101658.

Ramadan WS, et al. (2024) Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives. iScience, 27(1), 108659.

Egger T, et al. (2024) Spatial organization and functions of Chk1 activation by TopBP1 biomolecular condensates. Cell reports, 43(4), 114064.

Randolph ME, et al. (2024) RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. iScience, 27(2), 108925.

Wang Y, et al. (2024) NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors. Cell genomics, 4(5), 100550.

Arends T, et al. (2024) DUX4-induced HSATII transcription causes KDM2A/B-PRC1 nuclear foci and impairs DNA damage response. The Journal of cell biology, 223(5).

Zhu S, et al. (2023) SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses. Molecular cell, 83(4), 539.

Zhang Q, et al. (2023) VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinoma. Cellular oncology (Dordrecht), 46(4), 1001.

Pereira C, et al. (2022) Multiple 9-1-1 complexes promote homolog synapsis, DSB repair, and ATR signaling during mammalian meiosis. eLife, 11.

Egger T, et al. (2022) A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. *Scientific reports*, 12(1), 5422.

Zaher DM, et al. (2021) A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways. *Cancers*, 13(11).

Wang Z, et al. (2021) Epigenetic Dysregulation Induces Translocation of Histone H3 into Cytoplasm. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 8(19), e2100779.

Shen JZ, et al. (2021) FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. *Cell*, 184(2), 352.

Ling Q, et al. (2021) MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway. *EBioMedicine*, 69, 103441.

Shah RB, et al. (2021) FANCI functions as a repair/apoptosis switch in response to DNA crosslinks. *Developmental cell*, 56(15), 2207.

Lai KY, et al. (2021) LanCLs add glutathione to dehydroamino acids generated at phosphorylated sites in the proteome. *Cell*, 184(10), 2680.